Co-founded by Adyen's former CTO, Tebi helps restaurants, bars and other hospitality businesses manage their operations with ...

Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem ...

Galaxy Therapeutics, a privately held, clinical-stage medical device company focused on treating brain aneurysms, today announced the completion of enrollment in the primary cohort of its SEAL IT IDE ...

For these, Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) , which focuses on infectious diseases, and a merger agreement with Evofem.

announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”) has delivered notice (the “Termination Notice”) purporting to terminate the arrangement agreement dated April 1, 2024 between the ...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Aditxt, Inc. (ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising ...

MOUNTAIN VIEW, Calif., April 09, 2025--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to ...

MOUNTAIN VIEW, Calif., April 09, 2025--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform dedicated to accelerating promising health innovations, ...

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that it received notification ...

For these, Aditxt has entered into an arrangement agreement with Appili Therapeutics Inc. (TSX: APLI) (OTC: APLIF) , which focuses on infectious diseases, and a merger agreement with Evofem.

Aditxt, Inc., a pharmaceutical company with a market capitalization of $2.27 million, has modified its merger plans with Evofem Biosciences (OTC:EVFM), Inc., according to a recent SEC filing.

Aditxt, Inc. (NASDAQ:ADTX), a pharmaceutical company specializing in the development of treatments for immune-related diseases, has amended its merger agreement with Evofem Biosciences (OTC ...